JPS60258194A - Dihydropyridine derivative - Google Patents

Dihydropyridine derivative

Info

Publication number
JPS60258194A
JPS60258194A JP11371884A JP11371884A JPS60258194A JP S60258194 A JPS60258194 A JP S60258194A JP 11371884 A JP11371884 A JP 11371884A JP 11371884 A JP11371884 A JP 11371884A JP S60258194 A JPS60258194 A JP S60258194A
Authority
JP
Japan
Prior art keywords
group
compound
phenyl
formula
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11371884A
Other languages
Japanese (ja)
Inventor
Yoshiaki Tsuda
津田 嘉章
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP11371884A priority Critical patent/JPS60258194A/en
Publication of JPS60258194A publication Critical patent/JPS60258194A/en
Pending legal-status Critical Current

Links

Abstract

NEW MATERIAL:A compound of formula I (R1, R2, R3, R4 are lower alkyl; Ar is naphthyl, phenyl which may be substituted with 1-3 different or identical substituents selected from nitro, halogen, alkyl, hydroxy, cyano and others). EXAMPLE:Ethyl 1,4-dihydro-5-dimethoxyphosphinyl-2,6-dimethyl-4(3-nitrophenyl)- 3-pyridinecarboxylate. USE:Antihypertension, remedy for circulatory disorders, antiarteriosclerotic. PREPARATION:For example, the reaction of a compound of the formula: ArCHO such as m-nitrobenzaldehyde with another compound of formula II (such as ethyl 3-aminocrotonate and the third compound of formula III (such as dimethyl 2-oxopropyl phosphonate is carried out.

Description

【発明の詳細な説明】 本発明はジしド0ヒリジン誘導体に関する。[Detailed description of the invention] The present invention relates to dihydrohyridine derivatives.

発明の目的、構成及び効果 本発明のジしド0じリジン誘導体は、文献未載の新規化
合物であって、下記一般式(1)で表わされる。
Object, Structure, and Effects of the Invention The di-0-lysine derivative of the present invention is a novel compound that has not been described in any literature, and is represented by the following general formula (1).

〔式中R□、R2、R3及びR4は同−又は異なって低
級アルキル基を示す。Ar はナフチル基又は置換基と
してニド0基、ハロゲン原子、ハロゲン原子を有するこ
とのある低級アルキル基、しドロ士シ基及びシアノ基か
らなる群から選ばれた少くとも1種を1〜3個有するフ
ェニル基を示す。〕本明細書において、Ri、R2、R
3及びR4で示される低級アルキル基としては、例えば
メチル、エチル、プロピル、イソプ0じル、ブチル、イ
ソプチル・5ee−ブチル・を−づチル、ペンチル、イ
ソペンチル、ネオペンチル、へ士シル基等の直鎖状又は
分枝鎖状の炭素数1〜6のアル中ル基を挙げることがで
きる。Ar で示されるフェニル基上の置換基の位置と
しては特に限定がなく、またその置換基は同一でも異な
っていてもよい。フェニル基上の置換基であるハロゲン
原子としては、弗素、塩素、臭素、沃素原子等が例示で
き、ハロゲン原子を有することのある低級アルキル基と
しては、メチル、エチル、プロピル、イソプロピル・づ
チル・ l−ブチル、七ノフルオOメチル、tツク00
メチル、七ノづ〇七メチル、七ノヨードメチル、ジフル
オロメチル、トリフルオロメチル、トリク00メチル、
トリプロ上メチル、2.2.2−トリフジオ0エチル、
2.2.2− )リフo o’エチル、2、2.2−ト
リプo’eエチル基等を例示できる。置換基としてニド
0基、ハロゲン原子、ハロゲン原子を有することのある
低級アルキル基、しドロ士シ基及びシアノ基からなる群
から選ばれた少くとも1種を1〜3個有するフェニル基
の具体例としては、例えば2−ニド0フエニル、3−ニ
ド0フエニル、4−ニド0フエニル、2−り0ルフエニ
ル、3−プ0ムフェニル、4−フルオロフェニル、4−
ヨードフェニル、3−トリフルオDメチルフ′エニル、
3−(2,2,2−)リフルオロエチル)フェニル、2
−メチルフェニル、3−メチルフェニル12−シアノフ
ェニル、3−シアノフェニル、3.5−ジ−ターシャリ
−ブチル−4−しドロ+ジフェニル、2−り0o−5−
ニド0フエニル、2.3−ジグ00フエニル、2,4−
ジクooフェニルS2−り0ロー6−フルオロフェニル
、5−り00−2−ニド0フエニル、2.3−、; シ
トロ士ジフェニル\2,5−ジメチルフェニル、5−し
ドロ十シー2−ニド0フXニル・2・4・6−トリメチ
ル 1フエニル基等を挙げることができる。゛またナフ
チル基としては、■−ナフチル、2−jフチル基等を挙
げることができる。
[In the formula, R□, R2, R3 and R4 are the same or different and represent a lower alkyl group. Ar is a naphthyl group or 1 to 3 substituents of at least one selected from the group consisting of a nido group, a halogen atom, a lower alkyl group that may have a halogen atom, a cyano group, and a cyano group. indicates a phenyl group. ] In this specification, Ri, R2, R
Examples of lower alkyl groups represented by 3 and R4 include direct groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl/5ee-butyl/butyl, pentyl, isopentyl, neopentyl, and hesiyl groups. Examples include chain or branched alkyl groups having 1 to 6 carbon atoms. The position of the substituent on the phenyl group represented by Ar is not particularly limited, and the substituents may be the same or different. Examples of halogen atoms as substituents on phenyl groups include fluorine, chlorine, bromine, and iodine atoms, and examples of lower alkyl groups that may have halogen atoms include methyl, ethyl, propyl, isopropyl, butyl, and l-butyl, 7-fluoro-methyl, ttsuk00
Methyl, 7-no-7 methyl, 7-iodomethyl, difluoromethyl, trifluoromethyl, tric-00 methyl,
Tripromethyl, 2.2.2-trifudioethyl,
2.2.2-) Ri-o'-ethyl, 2,2,2-trip-o'e-ethyl groups, etc. can be exemplified. Specific examples of phenyl groups having 1 to 3 substituents of at least one selected from the group consisting of a nido group, a halogen atom, a lower alkyl group that may have a halogen atom, a cyano group, and a cyano group. Examples include, for example, 2-nido-phenyl, 3-nido-phenyl, 4-nido-phenyl, 2-di-olphenyl, 3-phenyl, 4-fluorophenyl, 4-
Iodophenyl, 3-trifluoro D-methylphenyl,
3-(2,2,2-)lifluoroethyl)phenyl, 2
-Methylphenyl, 3-methylphenyl 12-cyanophenyl, 3-cyanophenyl, 3,5-di-tert-butyl-4-dihydro+diphenyl, 2-di0o-5-
nido0 phenyl, 2,3-zig00 phenyl, 2,4-
Dikoo phenyl S2-di0-6-fluorophenyl, 5-di00-2-nido-0 phenyl, 2,3-; Examples include 0 phenyl group, 2,4,6-trimethyl, and 1 phenyl group.゛Also, examples of the naphthyl group include ■-naphthyl and 2-j phthyl groups.

上記一般式(1)で表わされるジしド0じリジン誘導体
は、優れた血管拡張作用、血圧降下作用及び抗動脈硬化
作用を有しておシ、抗高血圧剤、心臓ないし脳循環障害
治療薬、抗動脈硬化症剤等として有用である。
The di-0-lysine derivative represented by the above general formula (1) has excellent vasodilation, hypotensive and anti-arteriosclerotic effects, is an antihypertensive agent, and a therapeutic agent for cardiac or cerebral circulation disorders. , is useful as an anti-arteriosclerosis agent, etc.

上記一般式(1)で表わされる本発明の化合物は、種々
の方法によシ製造されるが、その−例を挙げれば以下に
示す方法に従い製造される。
The compound of the present invention represented by the above general formula (1) can be manufactured by various methods, and examples thereof include the following method.

(1) <W’) 〔式中R1、R2、R3、Ra及びArは前記に同じ。(1) <W’) [In the formula, R1, R2, R3, Ra and Ar are the same as above.

〕出発原料として用いられる一般式(It)の化合物、
一般式@)の化合物及び一般式(IV)の化合物は、い
ずれも公知の化合物であるか又は従来公知の方法に従っ
て容易に製造され得る化合物である〔J。
] A compound of general formula (It) used as a starting material,
The compound of general formula @) and the compound of general formula (IV) are both known compounds or compounds that can be easily produced according to conventionally known methods [J.

Am、Cktm、 5tyC,、67、lO17(19
45)、テトラヘトロンレター、21.1961(19
65) 等参照〕。
Am, Cktm, 5tyC,, 67, lO17 (19
45), Tetrahetron Letter, 21.1961 (19
65) etc.].

上記反応は、無溶媒下又は適当な溶媒中にて行なわれる
。溶媒としては、反応に不活性なものである限シ公知の
ものをいずれも使用でき、例えばメタノール、エタノー
ル1イソづ0パノール等のアルコール類、ベンゼン、ト
ルニジ、十シレン等の芳香族炭化水素類、り00ホルム
、塩化メチレン等のハロゲン化炭化水素類、テトラしド
ロフラン等のエーテル類、ヒリジン、酢酸、アセトニト
リル、N、N−ジメチルホルムアミド等を挙げることが
できる。一般式(1)の化合物、一般式(・■)の化合
物及び一般式(mV)の化合物の使用割合としては、特
に限定がなく広い範囲内から適宜選択することができる
が、上記3者のうちのいずれかの化合物IYニルに対し
て他の2つの化合物をそれぞれ1〜1.5七ル程度使用
するのがよい。上記反応は、通常20〜200°C程度
、好ましくは50〜150°C程度にて好適に進行し、
一般に0.5〜20時間で完結する。
The above reaction is carried out without a solvent or in a suitable solvent. As the solvent, any known solvent that is inert to the reaction can be used, such as alcohols such as methanol and ethanol, and aromatic hydrocarbons such as benzene, tornidi, and silane. Examples include halogenated hydrocarbons such as 000 form and methylene chloride, ethers such as tetrahydrofuran, hyridine, acetic acid, acetonitrile, and N,N-dimethylformamide. The proportions of the compound of general formula (1), the compound of general formula (・■), and the compound of general formula (mV) are not particularly limited and can be appropriately selected from a wide range. It is preferable to use about 1 to 1.57 units of each of the other two compounds for each compound IY. The above reaction normally proceeds suitably at about 20 to 200°C, preferably about 50 to 150°C,
Generally completed in 0.5 to 20 hours.

以上の方法によって製造される新規なりしド0ヒリジン
誘導体(1)は、従来公知の分離精製手段、例えば濃縮
、抽出、り0マドクラフイー、再沈殿、再結晶等を適宜
用いることによシ、反応混合物から単離精製することが
できる。
The novel phosphorylated hyridine derivative (1) produced by the above method can be prepared by reaction by appropriately using conventionally known separation and purification means such as concentration, extraction, crystallization, reprecipitation, recrystallization, etc. It can be isolated and purified from the mixture.

本発明化合物は、単独で又は他の組成物と共に例えば、
錠剤、カプセル剤、顆粒、粉末、注射剤等の形態で経口
的又は非経口的に投与できる。投与量は投与ルート、症
状、患者の体重、年令等によっても異なるが、経口投与
の場合通常成人1日当D1〜50〜程度であり、1日l
〜数回に分けて投与するのが望ましい。
The compounds of the present invention may be used alone or together with other compositions, for example:
It can be administered orally or parenterally in the form of tablets, capsules, granules, powders, injections, and the like. The dosage varies depending on the administration route, symptoms, patient's weight, age, etc., but in the case of oral administration, it is usually about D1-50 per day for adults,
It is preferable to administer the drug in several doses.

実 施 例 以下に実施例を掲げる。Example Examples are listed below.

実施例 1 m−ニトロベンズアルデヒド(1,6F)、3−アミッ
ク0トン酸エチル(1,3f)、ジメチル(2−才子ソ
プ0じル)ホスホネート(1,7f)及びイソプOパノ
ール10m1の混合物を20時間加熱還流後溶媒を留去
した。残留物をり0マド(シリカゲル15011.り0
0ホルム−メタノール(101)で溶出)で精製して得
られる粉末を酢酸エチル−へ牛サンから再結晶し、融点
188〜+90°Cの1,4−ジしドロー5−ジメト+
シホスフイニル−2,6−、;メチル−4(3−ニド0
フエニル)−3−ヒリジンカルボン酸エチルエステルを
得た。
Example 1 A mixture of m-nitrobenzaldehyde (1,6F), ethyl 3-amic acid (1,3f), dimethyl (2-amic acid) phosphonate (1,7f) and 10 ml of isopropanol was prepared. After heating under reflux for 20 hours, the solvent was distilled off. Remove the residue (silica gel 15011.0)
The powder obtained by purification with 0 form-methanol (101) was recrystallized from beef starch into ethyl acetate to give a 1,4-dimethane with a melting point of 188 to +90°C.
Cyphosphinyl-2,6-; Methyl-4(3-nido0
Phenyl)-3-hyridinecarboxylic acid ethyl ester was obtained.

実施例2〜12 上記実施例と同様にして下記表に示す化合物が製造され
る。
Examples 2 to 12 The compounds shown in the table below are produced in the same manner as in the above examples.

1、: N M R(CDCl、 ) 実施例2 δ− !、 亘5 (3H,t、J=7 、 QHx、C00
CH2C1l 3)3、70(3H,d、 J−11,
2ng、 −装<ocn3) ) − 3,84〜4.24(27/、 m、 −COOCH,
CD3)5、58 (IH,d、 J−9,2HI、 
(:’(4)−”)6、38(1#、 bread d
、 J−3,6Hz、〉NIL)11・ 実施例12 δ− 1,26(3H,t、 /−7,QRz、 COOCC
00CII2C、38(+8H,r、 −CCCH,)
3X2 )? 3、10(3H,d、 J−11,2H1,−1:<Q
C”3) )3、33(3#、 d、 /−11,2H
z、−鼻(OCI!、))4、11 (2#、 q、 
J−7,Qllr、 C00CH,CH,)4、53 
(IH,d、 /−10,8H1,C(4)−#)5、
00 (1’//、 s、 −OH)5.89(IH,
brtrad d、J−5,4Hz、/NH)1H (以 上) 手続補正書(睦) 3、補正をする者 事件との関係 特許出願人 4、代理人 大阪市東区平野町2の10沢の鶴ヒル電話06−203
−0941 (勺自発 6、補正により増加する発明の数 補 正 の 内 容 l 明細書第13頁第4行r 3.10 Jとあるをr
3.15Jと訂正する。
1,: NMR(CDCl, ) Example 2 δ-! , Wataru 5 (3H, t, J=7, QHx, C00
CH2C1l 3) 3, 70 (3H, d, J-11,
2ng, -so<ocn3)) -3,84~4.24 (27/, m, -COOCH,
CD3) 5, 58 (IH, d, J-9, 2HI,
(:'(4)-”)6,38(1#, bread d
, J-3,6Hz, 〉NIL)11・Example 12 δ-1,26(3H,t, /-7,QRz, COOCC
00CII2C, 38 (+8H, r, -CCCH,)
3X2)? 3, 10 (3H, d, J-11, 2H1, -1:<Q
C"3))3,33(3#,d,/-11,2H
z, - nose (OCI!, )) 4, 11 (2#, q,
J-7,Qllr, C00CH,CH,)4,53
(IH, d, /-10,8H1,C(4)-#)5,
00 (1'//, s, -OH)5.89(IH,
brtrad d. Tsuru Hill Phone 06-203
-0941 (Shimoto 6, Contents of the amendment to the number of inventions to be increased by amendment l Page 13 of the specification, line 4 r 3.10 J is r
Corrected to 3.15J.

2 明細書第13頁第5行r3.33Jとあるをr3.
50Jと訂正する。
2. Page 13 of the specification, line 5 r3.33J is replaced by r3.
Corrected to 50J.

(以 上)(that's all)

Claims (1)

【特許請求の範囲】 ■ 一般式 〔式中R□、R2、R3及びR1,は同−又は異なって
低級アル士ル基を示す。Arはナフチル基又は置換基と
してニドO基、ハロゲン原子、ハロゲン原子を有するこ
とのある低級アルキル基、しド0牛シ基及びシアノ基か
らなる群から選ばれた少くとも1種を1〜3個有するフ
ェニル基を示す。〕 で表わされるジしドロヒリジシ誘導体。
[Claims] ■ General formula [In the formula, R□, R2, R3 and R1 are the same or different and represent a lower alkyl group. Ar is a naphthyl group or at least one selected from the group consisting of a nido group, a halogen atom, a lower alkyl group that may have a halogen atom, a cyano group, and a cyano group as a substituent. Indicates the phenyl group that it has. ] A dihydrohirijishi derivative represented by.
JP11371884A 1984-06-01 1984-06-01 Dihydropyridine derivative Pending JPS60258194A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11371884A JPS60258194A (en) 1984-06-01 1984-06-01 Dihydropyridine derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11371884A JPS60258194A (en) 1984-06-01 1984-06-01 Dihydropyridine derivative

Publications (1)

Publication Number Publication Date
JPS60258194A true JPS60258194A (en) 1985-12-20

Family

ID=14619381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11371884A Pending JPS60258194A (en) 1984-06-01 1984-06-01 Dihydropyridine derivative

Country Status (1)

Country Link
JP (1) JPS60258194A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563782B2 (en) 2003-03-28 2009-07-21 Nissan Chemical Industries, Ltd. T-type calcium channel blocker

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563782B2 (en) 2003-03-28 2009-07-21 Nissan Chemical Industries, Ltd. T-type calcium channel blocker

Similar Documents

Publication Publication Date Title
WO1988002365A1 (en) Cyclic amine derivatives
JPS5822119B2 (en) Dithiol derivative
JPS6360755B2 (en)
KR860001865B1 (en) Process for preparing 2&#39;-deoxy-5-substituted uridine derivatives
JPS63290868A (en) Diketopiperazine derivative and salts thereof
JPS60258194A (en) Dihydropyridine derivative
TWI374878B (en) Phenanthrenone compounds, compositions and methods
JPH01313464A (en) Alkylpyperadinylpyridine being blood sugar level lowering agent
JP2838282B2 (en) Vasospasm therapeutic agent
WO1995005825A1 (en) Circulatory disturbance ameliorant
JPS63225354A (en) Azetidinone derivative
JP2577994B2 (en) Cerebral blood flow enhancer
JPS63233992A (en) Dihydropyridine-5-phosphonic acid cyclic esters
JP3049816B2 (en) Inotropic drugs
JPS6368591A (en) Optically active dihydropyridine-5-phosphonic acid ester
JP3049284B2 (en) Hydantoin derivatives and preventive and therapeutic agents for diabetic complications and cardiovascular diseases using the same as active ingredients
WO2000068231A1 (en) Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
JPH01275591A (en) Dihydropyridine-5-phosphonic acid derivative
JPH08225450A (en) Lipid oxidation suppressor
JPS61293981A (en) 12b-substituted 1-hydroxymethyl-octahydroindo- (2,3-a)quinolidine derivative and its production and pharmaceutical composition containing the same
JPH0733661A (en) Agent for preventing and treating cerebral disease
JPS63115889A (en) 2-amino-1,4-dihydropyridine derivative
JPH05279255A (en) Uric acid excretion promotor
JPH054396B2 (en)
JP3571114B2 (en) Narcotic antagonists